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The rapid approach of capitated reimbursement mandates that providers 
examine their practice patterns associated with all surgical procedures. 
Documentation f (1) the complications associated with these procedures and 
(2) the additional hospital costs associated with the management of these 
complications i critical for comprehensive fiscal accountability. This study 
analyzed (1) the feasibility of obtaining accurate hospital cost data specific for 
complications and (2) the outcome in terms of fully loaded hospital costs 
generated in the management of the most common surgical complications 
associated with pacemaker and nonthoracotomy implantable defibrillator 
therapies. Between July 1989 and September 1994, a total of 1031 pacemaker 
and 105 implantable defibrillator procedures were performed by a cardiac 
surgeon in a tertiary-level teaching hospital setting. The additional fully loaded 
hospital costs were determined by (1) correlating clinical data from the 
complete medical record with complete hospital charge data for the admis- 
sion(s) related to the complication, (2) carving out complication-related 
charges based on the clinical data, (3) converting complication-related charges 
to fully loaded costs based on conversion factors in effect at the time of service, 
and (4) correlating cost with hospital net reimbursement and payor source. 
The feasibility study determined that accurate and reliable cost data specific to 
complications can be obtained, although the process was cumbersome and 
difficult. The outcomes study determined that mean fully loaded complication 
costs were $4345 --- $1540 for pacemaker lead revision and $4879 - $3167 for 
implantable defibrillator lead dislodgment, $24,459 - $14,585 for pacemaker 
infection, and $13,736 -- $12,505 for defibrillator generator system malfunc- 
tion. The one infected defibrillator cost $57,213 to treat. Costs exceeded 
reimbursement for almost all Medicare patients with complications in this 
study, suggesting that similar shortfalls would occur under a capitation 
scheme. This information is critical to a complete understanding of the 
financial impact of interventional procedures in a capitated reimbursement 
environment. (J THOPO~C ARDIOVASC SURG 1996;111:742-52) 
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O ver the past 10 years device therapy for cardiac arrhythmias has evolved dramatically, 1 including 
the advent of nonthoracotomy implantable cardio- 
verter-defibrillators (NT-ICDs) 2-4 and dual-cham- 
ber, rate-responsive pacemaker systems with mode- 
switching capabilities. 57 With approximately 350,000 
individuals dying of sudden cardiac death each year, 
the potential impact of ICD therapy in prevention of 
this lethal event remains extremely high) The increas- 
ing age of the United States population assures that 
pacing therapy for bradycardia will continue to be a 
major therapeutic option well into the next century? 
Despite their effectiveness,5, ~0, 11 interfacing 
these two high- technology antiarrhythmic therapies 
into the setting of managed care and capitated 
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reimbursement is becoming considerably more dif- 
ficult. 1a-14 The initial cost of these devices is high, 
and the life-long nature of the therapy is associated 
with significant longitudinal cost implications as 
well. 
For reasons related to the broad medical-specialty 
provider base 6 and the rapid development of tech- 
nology,13, 14 the clinical outcomes after pacemaker 
and NT- ICD therapy have become somewhat diffi- 
cult to accurately determine. Even more difficult to 
determine is the financial impact of acute and 
chronic complications of these therapies. These 
costs represent unanticipated and in many instances 
unrecoverable provider expenditures is in a man- 
aged care environment, as suggested by current 
Medicare reimbursement schemesJ 6 
The purpose of this analysis was twofold: first, to 
determine the feasibility of obtaining accurate and 
reliable fully loaded cost data specifically related to 
the management of complications of an interven- 
tional procedure; second, to determine the financial 
outcome (in terms of the additional, fully loaded 
hospital costs) generated by the appropriate man- 
agement of complications of pacemaker and ICD 
therapy at Washington University School of Medi- 
cine and Barnes Hospital. 
Methods 
Clinical series. The study interval extended between 
July 1, 1989, and September 1, 1994. During this time 
interval, 1031 transvenous pacemaker systems were im- 
planted by one of the authors (T.B.F.) at Barnes Hospital, 
as an integral part of the Washington University Pace- 
maker Service] From 1989 to 1991, the majority of 
implants were performed on an inpatient basis; over the 
last 3 years of the study interval this shifted to a predom- 
inance of outpatient procedures. 
During this same time interval, 331 ICD procedures 
were performed by the same surgeon in conjunction with 
the members of the Section of Electrophysiology of
Barnes Hospital. Of these 331 implants, a total of 105 
first-time devices were implanted uring the past 2 years 
as nonthoracotomy systems (NT-ICD), under a variety of 
clinical investigational protocols ponsored by the Food 
and Drug Administration. 
Identification of complications. All patients were fol- 
lowed up in the Pacemaker Clinic or Defibrillator Clinic at 
Washington University. Essentially 100% follow-up was 
provided for all patients; pacemaker implant and fol- 
low-up information were stored online in a customized 
pacemaker follow-up computer system (Paceart, Inc., 
Paramus, N.J.), and a similar in-house system was used for 
the ICD patients. All complications that developed in the 
follow-up period were identified and managed at Barnes 
Hospital. 
In addition to these in-house patients, a number of 
patients with preexisting complications were transferred 
to Barnes Hospital for definitive therapy. 
For the purposes of this study, all common complica- 
tions in the series of patients were analyzed. For pace- 
maker patients these included (1) lead dislodgment ne- 
cessitating operative repositioning or lead fracture 
necessitating replacement for pacemaker implants, (2) 
infection of the pacemaker system, and (3) generator 
pocket hematoma formation ecessitating operative de- 
compression. For NT-ICD patients these included (1) 
lead dislodgment or fracture of the nonthoracotomy lead 
system, (2) system infection, (3) generator malfunction 
necessitating surgical reexploration/replacement, and (4) 
system modification owing to threshold elevation ecessi- 
tating surgical reexploration and revision. 
Financial analysis. Both in-house and transfer patients 
having one of these complications atany time during the 
study interval were included in the financial analysis. 
Feasibility study. From review of the complete medical 
record, those aspects of the patient's clinical course that 
were directly attributable to the complication were iden- 
tified. In addition, the following variable parameters were 
identified: hospital ength of stay (total LOS), the LOS 
resulting from treatment of the complication (complica- 
tion LOS), the number of minutes in the operating room 
required for any complication-related surgical proce- 
dure(s), any device(s) implanted, and any intensive care 
requirement. At the same time, the hospital bill contain- 
ing all per diem itemized charges, adjustments, and pay- 
ment data for the hospitalization during which the com- 
plication was treated were obtained from the billing office 
at Barnes Hospital. 
Two financial analysis categories of patients were iden- 
tified: Type 1 patients were admitted specifically for 
treatment of the complication (e.g., admission for explan- 
ration of an infected pacemaker system), and the charges 
for the entire hospitalization were included in the analysis; 
in type 2 patients the complication developed uring the 
hospitalization i  which the initial implant was performed 
(e.g., acute lead dislodgment after pacemaker implanta- 
tion). The hospital days resulting from treatment of that 
complication were documented from the clinical data, and 
all the charges incurred during that time interval in the 
treatment of that complication were identified and carved 
out from the total hospital charges for that admission. 
Once the charges were identified, the Barnes Hospital 
finance oNce used Barnes Hospital financial data software 
to convert he actual cost incurred by the hospital for that 
provision of care at the time of service. These hospital 
costs were fully loaded, and the accuracy of these costs 
was verified by internal review in the finance office. 
Outcome financial analysis for complications of pace- 
maker and ICD therapy. Total hospital charges, total 
hospital costs (costs for entire hospitalization), total com- 
plication costs, and carve-out complication costs (costs for 
complication treatment) were determined. Complication 
costs were defined as beginning when a definitive compli- 
cation diagnosis was established and ending when inpa- 
tient therapy for that complication was satisfactorily com- 
pleted. In addition, contractual adjustments o revenue, 
total revenue, and source of revenue (Medicare vs corn- 
7 4 4 Ferguson et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
April 1996 
mercial pay) were documented for each patient. The 
number of patients in each category of complications in 
the pacemaker and NT-ICD groups, as well as the mean _+ 
standard eviation of each financial category, was calcu- 
lated. Profit/loss was calculated by subtracting total costs 
from total revenue for type 1 patients only (entire hospi- 
talization was for the complication); carve out of revenues 
was not verifiable and, therefore, was not performed in 
the analysis. Charge and cost data are expressed as mean 
-+ standard eviation. 
Results 
Clinical series. The overall clinical results associ- 
ated with the 1031 pacemaker procedures included 
825 new implants (65% dual-chamber devices), 49 
lead repositions, 93 generator changes, 17 explants 
of infected devices, and 47 other miscellaneous 
procedures. The 105 NT-ICD implants included 
primarily investigational systems from different 
manufacturers. 
There were no deaths related to the 1136 proce- 
dures included in the study (Table I). 
The overall in-house incidence of pacemaker sys- 
tem infection was 0.58% (6/1031). An additional 11 
patients with pacemakers were transferred from 
outside institutions for definitive therapy of infected 
systems. The in-house lead reposition/replacement 
rate was 4.1% (37/902 procedures involving lead 
placement); an additional 12 patients were trans- 
ferred from outside institutions for definitive ther- 
apy of lead-related complications. Pocket hemato- 
mas necessitating evacuation developed in four 
patients with pacemakers; all patients were receiving 
systemic anticoagulation for other medical condi- 
tions, and all were over-anticoagulated in restarting 
their medication after implantation. 
One NT-ICD system infection occurred (1/105, 
0.95%) at the site of a subcutaneous patch in a patient 
randomized to a lead-plus-patch protocol. The entire 
ICD system was explanted and, after appropriate 
antibiotic and empiric amiodarone therapy, a new, 
lead-only NT-ICD system was implanted. 
Four patients had endocardial lead dislodgments 
(n = 2) or fractures (n = 2), requiring reexploration 
with repositioning or extraction and replacement. 
One additional patient had radiologically identified 
lead migration and incisional drainage necessitating 
antibiotic therapy. ICD system sensing problems 
necessitating reexploration developed in two pa- 
tients; generator malfunction ecessitated evice 
replacement in one of these patients. 
Two additional patients, one receiving systemic 
anticoagulation for severely depressed ventrieular 
function and the other receiving dialysis for chronic 
renal failure, had pocket hematomas that necessi- 
tated reexploration. In both cases the routine 
postimplantation test was performed as part of this 
procedure, and in both patients an acute rise in the 
defibrillation threshold was demonstrated. This rise 
in defibrillation thresholds necessitated lead reposi- 
tioning in one and the addition of a subcutaneous 
patch to the system in the second. 
Feasibility study. The ability of the finance office 
of Barnes Hospital to obtain accurate cost data 
before mid-1991 was limited. Therefore, 14 of the 49 
patients having total pacemaker lead repositioning 
who were treated before this time were excluded 
from the financial analysis. A previous study 7 had 
determined accurate cost data for patients having a 
pacemaker infection and being treated before 1991, 
and these data were included in the analysis. Accu- 
rate fully loaded cost data were obtained on the 
remaining patients with pacemaker and ICD com- 
plications. 
The process of retrospective data acquisition, 
correlation of clinical and charge data, determina- 
tion of carve-out charges, and conversion to costs 
was a tedious and difficult one, with many determi- 
nations and conversions made on an item-by-item 
basis. 
Outcome study. Approximately 70% of the over- 
all pacemaker implant population of 1031 patients 
were Medicare recipients; this percentage was 
slightly higher in the complication group included in 
the financial analysis. The mean total LOS and 
complication LOS was longest for the infection 
subgroup; the added complication LOS for the 
hematoma subgroup reflected, in part, additional 
hospital days to manage the patient's anticoagula- 
tion status (see Table I). 
In the ICD complication group, the number of 
Medicare recipients was lower, at 44.5%. Complica- 
tion LOS was longest for the one patient with 
infection and second longest for the patients with 
elevated efibrillation thresholds. 
Fully loaded hospital costs generated by the treat- 
ment of the pacemaker complications are shown in 
Table II. Note that hospital charges did not accu- 
rately reflect any category of true hospital costs; 
moreover reimbursement, as mean revenue/loss, 
varied for each complication and between reim- 
bursement sources irrespective of charges or costs. 
System infection was the most expensive complica- 
tion, averaging $24,459 _+ $14,585 in added costs; 
these costs were primarily related to the additional 
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Table I. Complication data 
Pacemakers 
Procedures (n - 1031) 
0% Mortality 
In-house pacemaker infections Oz = 6) 0.58% 
Outside referrals (n = 11) 
In-house pacemaker lead related (n = 37) 4.1% 
Outside referrals (n = 12) 
In-house hematoma (n = 4) 0.38% 
Complications 
Lead related (n = 49) 
Mean age (yr) 64.9 _+ 15.4 
Mean total LOS (days) 12.5 _+ 7.8 Range 1-56 
Mean complication LOS (days) 2.5 + 0.7 Range 1-10 
Infection (n = 17) 
Mean age (yr) 63.9 _+ 17.4 
Mean total LOS (days) 25.6 _+ 33.9 Range 4-134 
Mean complication LOS (days) 15.9 _+ 7.6 Range 4-31 
Hematoma Oz = 4) 
Mea n age (yr) 63.5 + 16.5 
Mean total LOS (days) 39.0 _+ 52.7 Range 9-118 
Mean complication LOS (days) 5.5 _+ 2.8 Range 2-9 
NT-ICD 
Procedures (n = 105) 
0% Mortality 
Lead related (n = 5) 4.9% 
System malfunction (n 2) 1.9% 
High DFTs (n = 2) 1.9% 
Infection (n = 1) 0.95% 
Complications 
Lead related (n = 5) 
Mean age 44.3 _+ 17.5 
Mean total LOS (days) 3.4 _+ 1.6 Range 2-6 
Mean complication LOS (days) 2.8 + 0.8 Range 2-4 
System malfunction (n = 2) 
Mean age 69.5 _+ 10.6 
Mean total LOS (days) 9.0 _+ 7.1 Range 4-14 
Mean complication LOS (days) 2.5 _+ 2.1 Range 1-4 
High DFTs (n -  2) 
Mean age 46.5 -+ 24.7 
Mean total LOS (days) 21.5 +- 3.5 Range 19-24 
Mean complication LOS (days) 11.0 + 4.2 Range 8-14 
Infection Oz = 1) 
Age 52 
Mean total LOS (days) 19 
Mean complication LOS (days) 19 
LOS, Length of hospital stay; total LOS, LOS for entire hospitalization; complication LOS, hospital days beginning at the time a definitive complication 
diagnosis was established and ending with completion of therapy for that complication; DFTs, defibrillation thresholds. 
LOS required for antibiotic therapy, the replace- 
ment pacemaker systems required, and the use of 
cardiopulmonary bypass for removal of intracardiac 
infected material (n = 4 patients). Carve-out costs 
in the two patients with additional medical problems 
and prolonged hospitalizations were higher, at 
$34,987 _+ $7,795. The type 1 costs were $23,056 _+ 
$14,859. 
Hematoma evacuation and lead-related complica- 
tions were less expensive. Carve-out costs for the 
four patients in whom a hematoma developed were 
$6187 + $2631; because of the small number of 
patients, type 1 costs were not determined. The 
added carve-out cost for the 35 lead-related compli- 
cations was $4345 _+ $1540. 
In Fig. 1 the profit/loss data for type 1 patients 
undergoing pacemaker lead reposition are com- 
pared with the reimbursement amount by payor, 
calculated as reimbursement minus type 1 cost. The 
analysis for the total lead-related group is shown as 
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Table II. Cost of pacemaker complications 
Complications with complete 
financial data (n = 56) 
Total aggregate charges $3,131,341 
Total hospital costs $1,708,890 
Mean $30,516 _+ $38,755 
Total complication costs $592,664 
Mean $10,583 _+ $12,222 
Lead related (n = 35) 
Total charges $1,590,270 
Mean $45,436 _+ $53,757 
Total hospital costs $872,579 
Mean $24,931 _+ $29,535 
Total complication costs $152,106 
Mean $ 4,345 _+ $1,540 
Type 2 costs (n 21) $90,376 
Mean $ 4,303 _+ $1,442 
Type 1 costs (n = 14) $61,730 
Mean $ 4,409 _+ $1,732 
Mean revenue/loss $ 1,706 _+ $2,272 
Medicare (n : 8) $ 1,650 _+ $2,983 
C Pay (n - 6) $ 1,780 -+ $974 
Infection (n = 17) 
Total charges $1,282,017 
Mean $75,413 _+ $100,663 
Total hospital costs $690,172 
Mean $40,598 _+ $52,189 
Total complication costs $415,808 
Mean $24,459 _+ $14,585 
Type 2 costs (n = 2) $69,975 
Mean $34,987 _+ $7,795 
Type 1 costs (n = 15) $345,833 
Mean $23,056 _+ $14,859 
Mean revenue/loss $ 5,863 _+ $5,263 
Medicare (n = 10) $ 6,354 + $5,522 
C Pay (n = 5) $ 6,827 _+ $12,477 
Hematoma (n = 4) 
Total charges $64,753 
Mean $64,753 _+ $79,270 
Total hospital costs $146,139 
Mean $36,534 _+ $46,202 
Total complication costs $24,750 
Mean $ 6,187 _+ $2,631 
Type 1 costsj Total complication costs = entire cost of hospitalization; type 
2 costs, carve-out complication costs; Medicare, Medicare reimbursement 
for type 1 patients only; C Pay, commercial payor eimbursement for type 
1 patients only, 
well. The hospital ost money as a whole on this 
population of patients; a small profit was made for 
all patients for both Medicare and commercial pay 
reimbursement sources, but the standard eviation 
of these data was large. 
Fig. 2 illustrates the profit/loss data for patients 
treated for pacemaker infections. Again, the total 
cost exceeded reimbursement i  this group of 17 
patients. In the 15 type 1 patients, the average loss 
was $5863 + $5263 for the hospital; this loss was 
exaggerated in the Medicare subgroup. Commercial 
payor reimbursement resulted in a mean profit, but 
the majority of these patients were treated in the 
early years of the study when cost shifting was more 
favorable than at present. 
The fully loaded costs incurred in the treatment of
NT-ICD complications were considerably higher 
(Table III). The one patient with an infected system 
required two hospitalizations and reimplantation f 
an entirely new endocardial system; this complica- 
tion resulted in actual costs of $57,213. Both pa- 
tients with hematomas and elevated efibrillation 
thresholds required additional operating room pro- 
cedures and had prolonged hospitalizations. Their 
treatment resulted in a mean additional cost of 
$38,864 _+ $4,069. Reexp!oration for a generator 
system malfunction was expensive--S13,736 _+
$12,505; this was in part due to the necessity of 
replacing the ICD device in one of these two 
patients. The costs incurred for lead repositioning or
replacement were similar to those for pacemaker 
lead problems--S4879 _ $3167. Interestingly, the 
frequency of this complication with both therapies 
was similar as well. 
Fig. 3 illustrates the cost/reimbursement a alysis 
for the NT-ICD complications in aggregate, because 
of the small number of patients with each compli- 
cation. Treatment of both Medicare (n = 3) and 
commercial pay (n = 4) type 1 patients resulted in a 
loss for the hospital ($1,164 _ $15,678 and $847 _+ 
$5496, respectively). 
Discussion 
The purpose of this study was twofold: (1) to 
determine the feasibility of acquiring accurate fully 
loaded cost data pertaining to treatment of compli- 
cations of interventional procedures and (2) to apply 
this approach in a financial outcomes tudy deter- 
mining the accurate, fully loaded hospital costs 
associated with the management of the most com- 
mon complications ofpacemaker and NT-ICD ther- 
apy. 
Feasiblity study. Determination of accurate 
fully loaded costs for hospitalizations has been 
difficult. 17 Hospital accounting practices have his- 
torically been based on charges. In certain aca- 
demic centers where the medical school did not 
own the teaching hospital, much of this charge 
information was considered proprietary. Cost 
shifting to cover losses incurred in treating unin- 
sured patients made hospital charges even less 
reflective of true incurred costs. Medicare and 
third-party payors placed restrictions on the min- 
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Fig. 1. Profit/loss analysis for pacemaker lead repositions, calculated as net revenue minus complication 
cost for the categories on the ordinate. Total H, total hospital costs (including both type 1 and type 2 
patients and including complication and non-complication-related costs; similarly, reimbursement is for the 
entire hospitalization irrespective of payor); Type 1, type 1 costs (where entire hospitalization was for 
treatment of the complication); Medicare, those type 1 patients whose costs were reimbursed by Medicare; 
C Pay, those type 1 patients whose costs were reimbursed by commercial payors; N, number of patients in 
each category; SD, standard eviation, expressed as a positive value only for emphasis. 
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Fig. 2. Profit/loss analysis for pacemaker infection, calculated as net revenue minus complication cost for 
the categories on the ordinate. Data are expressed as mean complication costs _+ standard eviation (SD); 
standard eviations are expressed as positive values only for emphasis. For abbreviations see Fig. 1. 
imum as well as maximum that hospitals can 
charge for certain services, further complicating 
determination of true costs from these charge 
data.16, is Overall, as demonstrated in this and 
other studies, charge data are of little value in 
assessing the true financial impact of a proce- 
dure. 19 
Even more difficult has been determination of the 
fully loaded costs associated with specific complica- 
tions of therapies or procedures. This is particularly 
problematic when the complications arise during an 
admission for an unrelated medical problem (e.g., 
carve-out complication costs). 
The present study demonstrates that accurate cost 
data can be obtained for complications of pace- 
maker and NT-ICD therapy. Furthermore, these 
complication-generated cost data can be carved out 
of otherwise medically complex hospitalizations. 
The reliability of this information is dependent on 
the accurate combination of clinical data from the 
medical record with relevant financial information. 
This same approach could be used, for example, to 
determine the costs associated with reexploration 
for bleeding after cardiac operations or complica- 
tions related to interventional cardiovascular p oce- 
dures. 
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Fig. 3. Profit/loss analysis for all NT-ICD complications, calculated as net revenue minus complication 
cost for the categories on the ordinate. Data are expressed as mean complication costs _+ standard eviation 
(SD); standard eviations are expressed as positive values only for emphasis. For abbreviations see Fig. 1. 
The study also suggests the need for simplified, 
prospective methods for determining cost estimates 
that are accurate and reliable and that can be used 
for prospective fiscal planning. ~°-22 For at least two 
reasons, recent changes in the nation's health care 
system have abruptly made acquisition of these 
financial outcomes data critical. First, providers are 
now becoming legally, medically, and financially 
accountable for cost, quality, and outcomes. 23Man- 
aged care contracting has altered the financial ia- 
bility of providers; for example; so-called case-cost 
contracting has led to the offering of guarantees for 
certain surgical procedures, covering all complica- 
tions for a specified period of time after the initial 
procedure. 24Capitation-based programs are offer- 
ing risk-bearing contracts, taking into account he 
frequency of the need for an intervention in a 
managed care population, as well as case and com- 
plication costs. For either contractual arrangement 
to be financially feasible for the provider, accurate 
determination of the incidence and the costs asso- 
ciated with appropriate treatment of the complica- 
tions is mandatory. 
Second, the decision to purchase services from 
providers under managed care contractural condi- 
tions is most frequently made by assessment of 
initial costs for procedures and diseases, 19 with 
much less emphasis placed on the longitudinal out- 
comes of those procedures. In this scheme, however, 
complications represent unanticipated future ex- 
penses representing potential financial shortfalls for 
the provider. Thus quality of service, defined in this 
case as minimalization of both acute and chronic 
procedure-related complications, assumes a new 
financial implication for providers of health care. 
Outcomes tudy. The present study has examined 
in a financial outcomes analysis the most common 
complications associated with pacemaker and NT- 
ICD therapy. Reasons for choosing these proce- 
dures include the expertise available in these thera- 
pies at Washington University, large implant patient 
populations for these devices, uniformity of care 
with a single surgeon implanting all devices, and 
complete follow-up.l' 7
The study has documented that treatment of 
these complications is expensive. For the duration of 
the study, 1989 to 1994, the total fully loaded cost 
incurred by Barnes Hospital for treatment of all of 
these complications (excluding the 14 patients hav- 
ing pacemaker lead reposition before 1991) was 
$779,804. Moreover, when the total hospital costs 
were compared with reimbursement, the hospital 
lost money on both pacemaker (Figs. 1 and 2) and 
NT-ICD patients (Fig. 3); this reflects the general 
clinical and payor status of many of these device 
recipients. 
Infection of device systems was the most expen- 
sive complication, primarily resulting from an ex- 
tended LOS, associated antibiotic therapy, and the 
replacement hardware. Not surprisingly, other com- 
plications resulting in prolonged LOS or more in- 
tensive services resulted in higher fully loaded costs 
to the hospital. 
Of note, the difference between an infection rate 
for pacemaker implantation of 0.5% and 5% repre- 
sents a difference of approximately $250,000 per 
year in provider costs. Infectious complication rates 
for pacemaker implantation reported in the litera- 
ture range from 0.5% to almost 20%. 7, 3o-33 At the 
current reimbursement rate for pacemaker implan- 
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tation paid by Medicare, this amount represents the 
equivalent of 10 or 11 new device implants. Even 
so-called minor complications, uch as lead dislodg- 
ments, are associated with significant aggregate x- 
pense. 
Complications associated with NT-ICD devices 
are considerably more expensive to manage than 
pacemaker complications. The true incidence of 
NT-ICD complications is difficult o determine from 
the literature, given the rapid development of this 
technology and the multiple settings for implanta- 
tion that are evolving. 2'20, 21, 25 Zipes and Roberts a° 
have reported an 18.9% incidence of invasive com- 
plications with endocardial implants (from 2807 
patients). Nunain and associates z5 recently reported 
an incidence of 36.5% ICD-related problems with 
tiered-therapy devices; 13.6% required some type of 
system revision at a mean of 8.6 months after the 
initial implant. Daoud and coworkers 26 have re- 
ported an unexpected late increase in defibrillation 
thresholds (greater than 10 joules), necessitating 
system revision, in a small number of patients with 
NT-ICD systems. These data may be compared with 
a 10% incidence in the present series. Although 
other studies have examined the "cost effectiveness" 
of ICD therapy as compared with other forms of 
antiarrhythmic therapy 13' 27 or as a first-line thera- 
py,28 the present study is the first to document the 
actual costs associated with treatment of complica- 
tions resulting from ICD therapy. The fully loaded 
cost generated in managing the single infected sys- 
tem in this series was considerably more than the 
published cost data for initial ICD implants. 13' 2e, 29 
This single ICD infection generated costs equivalent 
to three elective generator replacements; at Wash- 
ington University, replacements are done as a sur- 
gical outpatient procedure, but still result in costs 
approaching $20,000 per replacement. 1' 29 By way of 
reference for these cost data, the incidence of 
complications in the large series of patients exam- 
ined in this study is equal to or better than other 
results reported in the literature for 
pacemaker 7, 30-33 and ICD therapy, z' 20, 21, 25 From a 
financial perspective, it is clear that a significant 
incidence of any of these complications quickly 
generates ignificant additional high fully loaded 
costs for the provider. 
The cost/reimbursement da a in this study were 
generated only from patients whose entire hospital- 
ization was related to the complication, so that the 
reimbursement amount accurately reflected the en- 
tire hospitalization, and the results are a cause for 
Table III. Cost of NT-ICD complications 
All complications (n = 10) 
Total aggregate charges 
Total hospital costs 
Mean 
Total complication costs 
Mean 
Type 2 complication costs (n - 3) 
Mean 
Type 1 complication costs (n = 7) 
Mean 
Mean revenue/loss 
Medicare (n = 3) 
Commercial pay (n = 4) 
Individual complications 
Infection (n = 1) 
Mean total cost 
Mean complication cost 
Lead rleated (n = 5) 
Mean total cost 
Mean complication cost 
High DFTs (n = 2) 
Mean total cost 
Mean complication cost 
Generator malfunction (n = 2) 
Mean total cost 
Mean complication cost 
$476,932 
$242,162 
$24,216 -+ $20,320 
$186,810 
$16,982 -+ $14,822 
$82,705 
$27,570 -- $19,771 
$104,190 
$13,023 + $11,658 
$ 966 +- $935 
$ 1,164 -+ $15,678 
$ 847-+ $5,496 
$57,213 
$57,213 
$ 4,879 -+ $3,167 
$ 4,879 -+ $3,167 
$52,596 -+ $815 
$38,864 -+ $4,069 
$32,269 -+ $13,703 
$13,736 -+ $12,505 
Type I costs, Total complication costs = entire cost of hospitalization; type 
2 costs, carve-out complication costs; Medicare, Medicare reimbursement 
for type 1 patients only; C Pay, commercial payor reimbursement fortyep 
1 patients only; DFTs, defibrillation thresholds. 
concern. These data (Figs. 1 to 3) demonstrate hat 
a shortfall on reimbursement of Medicare patients 
was experienced in almost all cases. It is anticipated 
that these reimbursement levels will continue to be 
reduced by Congress. ' 19, 33, 34 Moreover, the Medi- 
care population will continue to increase substan- 
tially in numbers well into the next century; this 
increase in patient number has been demonstrated 
to account for the majority of the increase in 
Medicare expenditures projected over this time 
interval. 34 
This study focused on complication-related costs 
of pacemaker and NT-ICD therapy, not the cost of 
initial implantation. VVI pacemaker placement in 
all patients and amiodarone therapy in lieu of 
NT-ICD therapy represent the most dramatic ost- 
saving options with respect to the initial implant 
procedure. With regard to complications, only two 
mechanisms exist for reduction of these costs: (1) 
reduce the incidence of the complications and (2) 
reduce the cost of treatment of the complications. 
Multiple studies have documented that the inci- 
dence of complications for interventional proce- 
dures increases significantly when the operator 
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and/or institution performs a subthreshold number of 
procedures per year. 31'32 Importantly, the present 
study also documents that there is an expected finan- 
cial liability, as well as a quality of care liability, 
associated with this degree of performance infrequen- 
cy, 18 particularly with respect o pacemaker and NT- 
ICD implantation. Furthermore, this financial iability 
is present irrespective of such issues as facility sites of 
implantation and/or the medical speciality of the im- 
planter. Currently, a number of options are available 
to reduce the cost of treatment of complications. 
These include shifting to outpatient therapy for intra- 
venous antibiotics, home-health nursing services, and 
implementation of anticoagulation therapy on an out- 
patient basis to minimize hospital LOS. 
This study has several important  l imitations. It is 
a prel iminary financial feasibil ity and outcomes 
analysis in a selected pat ient populat ion.  The num- 
ber of patients with complicat ions was small, and the 
financial analysis was l imited to only a 5-year study 
interval. In a number  of patients the devices were 
implanted under  clinical investigational protocols. 
A l though these costs were fully accounted for in this 
study, current clinical practice is different from 
several of those protocols. Finally, extremely rapid 
changes in device technology and health care provi- 
sion occurred during this study interval. 
Nevertheless, the analysis demonstrates directly 
that management  of complications of pacemaker  
and NT- ICD therapies is expensive. It demonstrates 
indirectly that compl icat ion-related costs can be an 
important  component  in the overall cost of device 
therapy. This is part icularly true in the Medicare 
pat ient populat ion or under circumstances in which 
device-related complicat ions are excessively preva- 
lent. Opportunit ies to reduce the incidence of com- 
plications, as well as the addit ional  costs of this 
therapy, will become increasingly important  o pro- 
viders and managed care organizations. Finally, this 
identif ication and quantif ication is a step toward the 
accurate financial assessment of this aspect of health 
care provision that directly links outcomes and costs. 
As more of the health care system in the Uni ted 
States moves to a managed care environment and 
toward capitated re imbursement,  information such 
as presented here for pacemaker  and ICD therapy 
will become increasingly important  for all types of 
interventional procedures.  
We gratefully acknowledge the expertise and assistance 
of Mr. Ron Trulove, in the finance office of Barnes 
Hospital, for his work on this project. 
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Discuss ion 
Dr. D. Glenn Pennington (St. Louis, Mo.). This study 
involved only hospital cost and not physician reimburse- 
ment. Is it not true that a complication would be excluded 
from all of the current procedural technology codes? In 
other words, is it not true that all of them refer to changes, 
for example, after the first 3 weeks? 
Dr. Ferguson. That is true in most but not all the cases. 
Some of these patients were treated several years after the 
initial event, but those problems till have to be consid- 
ered complications. When we get to single payment 
capitation, though, that is not going to be an issue, 
because we, as providers, are going to be left with the 
responsibility for treating these complications and we will 
not be able to bill specifically for them. 
Dr. Richard J. Shemin (Boston, Mass.). Dr. Ferguson, 
in reviewing, have you been able to identify any change in 
treatment protocols, practice guidelines, or critical path- 
ways for the treatment of these patients? Perhaps more 
outpatient reatment or other practice style changes 
would reduce the costs and generate at least a break even 
or a slight profit for the institution. 
Dr. Ferguson. We have attempted to treat these com- 
plications as expeditiously aspossible. The only complica- 
tions that really have been most difficult to treat are 
infectious complications because they require prolonged 
hospitalizations, and almost all necessitate explantation 
and reimplantation f expensive hardware. All of the lead 
repositions and evacuations were done as outpatient 
procedures. 
There was one difference that did come up that was 
time-related. The slight profit seen in the commercial 
payors in the infectious pacemaker group was derived 
from the early years, when cost shifting by those commer- 
cial providers was still a possibility. Their profit almost 
certainly was generated on that basis. In the current 
environment cost shifting is becoming more difficult, and 
I think even that subgroup of patients would lose money. 
Dr. Agustin Arbulu (Detroit, Mich.). I have a question 
about the infectious complication, because we had a 
similar incidence of infections in automatic ICDs. We just 
had our third infection in over 300 cases that we've done, 
particularly those with a nonthoracotomy approach, which 
comprise about two thirds of this population. The prob- 
lem is that we explanted the device immediately and then 
consulted our infectious disease experts. Even with the 
explanted paraphernalia they insisted that the patient 
undergo 4 to 6 weeks of intravenous antibiotic therapy. 
The problem is that the patient has the sudden death 
syndrome. How do you handle those cases? What is your 
protocol of management? 
Dr. Ferguson. That is an extremely difficult situation to 
manage. The experience with other types of hardware 
would dictate that those patients do require long-term 
antibiotic therapy. In the ICD patient population, the only 
option in most cases is to administer amiodarone for the 
window of time that they cannot have the ICD as a 
backup. Currently, that can usually be done on an outpa- 
tient basis with home antibiotics, but they all will have to 
have the ICD reimplanted at some point. There will 
probably be a small but finite incidence of sudden death in 
that population. 
Dr. Arbulu. Am I correct that you sent them home 
receiving the antiarrhythmic drugs? 
Dr. Ferguson. Yes, unless in the judgment of our 
electrophysiologists therisk of that was just too high, in 
which case the patient had to stay in the hospital the entire 
time. 
Dr. Anthony L. Moulton (Providence, R.I.). There is an 
increasing tendency for pacemakers to be implanted by 
persons without formal surgical training and in areas 
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outside the operating room. Was there as a correlation 
between your infection rate and the implantation physi- 
cian? Also, was there a greater expediency with which 
infectious complications were treated depending on the 
implanting physician? 
Dr. Ferguson. Not based on these data. All of these 
procedures were done by me at Washington University. 
There is, at least in the literature, a difference in the 
infectious complication rate reported in the surgical series 
as compared with the series reported by implantation i  
other environments and by cardiologists. The difference is
small, but it appears to be real. Although that assessment 
was not the purpose of this paper, what that means in 
terms of a hospital administrator is a difference between 
an infection rate of 0.5% and 4% or 5%. That could end 
up being a difference of $250,000 in true hospital costs at 
the end of a year. Maybe analyses such as these and others 
can be used to reintroduce the concept hat the quality of 
what is done and not just the initial costs is important in 
the long term. 
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